Genflow Biosciences PLC Announces Holding(s) in Company
Genflow Biosciences (OTC:GENFF) disclosure shows Jonathan Mark Swann increased his holding to 11.32% of voting rights in Genflow Biosciences on 23-Oct-2025, up from 8.40% in the prior notification.
The resulting position equals 55,861,278 voting rights. No financial instruments were reported; the notification lists completion in London on 23-Oct-2025 and states no additional information.
Genflow Biosciences (OTC:GENFF) la disclosure mostra che Jonathan Mark Swann ha aumentato la sua quota al 11,32% dei diritti di voto in Genflow Biosciences il 23-ott-2025, rispetto al 8,40% della precedente comunicazione.
La posizione risultante è pari a 55.861.278 diritti di voto. Non sono stati riportati strumenti finanziari; la comunicazione indica il completamento a Londra il 23-ott-2025 e non riporta ulteriori informazioni.
Genflow Biosciences (OTC:GENFF) la divulgación muestra que Jonathan Mark Swann aumentó su participación a 11,32% de los derechos de voto en Genflow Biosciences el 23-oct-2025, desde el 8,40% de la notificación anterior.
La posición resultante equivale a 55.861.278 derechos de voto. No se reportaron instrumentos financieros; la notificación indica la finalización en Londres el 23-oct-2025 y señala que no hay información adicional.
Genflow Biosciences (OTC:GENFF) 공시는 Jonathan Mark Swann이 Genflow Biosciences의 보통주 의결권 지분을 11.32%로 늘렸다고 보여주며, 이 내용은 2025-10-23에 이루어졌고, 이전 공시의 8.40%에서 증가했습니다.
이로써 해당 지분은 55,861,278 의결권에 해당합니다. 금융상품은 보고되지 않았고; 공시에는 런던에서 2025-10-23에 완료되었으며, 추가 정보는 없다라고 기재되어 있습니다.
Genflow Biosciences (OTC:GENFF) la divulgation montre que Jonathan Mark Swann a augmenté sa participation à 11,32% des droits de vote chez Genflow Biosciences le 23-oct-2025, contre 8,40% lors de la notification précédente.
La position résultante équivaut à 55.861.278 droits de vote. Aucun instrument financier n'a été signalé; la notification indique un achèvement à Londres le 23-oct-2025 et indique qu'aucune information supplémentaire.
Genflow Biosciences (OTC:GENFF) Offenlegung zeigt, dass Jonathan Mark Swann seine Beteiligung auf 11,32% der Stimmrechte bei Genflow Biosciences am 23-Oct-2025 erhöht hat, gegenüber 8,40% in der vorherigen Meldung.
Die resultierende Position entspricht 55.861.278 Stimmrechten. Es wurden keine finanziellen Instrumente gemeldet; die Meldung nennt den Abschluss in London am 23-Oct-2025 und gibt an, dass keine weiteren Informationen vorliegen.
Genflow Biosciences (OTC:GENFF) تفصح أن جوناثان مارك سوان زاد حصته إلى 11.32% من حقوق التصويت في Genflow Biosciences في 23-أكتوبر-2025، مقارنة بـ 8.40% في الإخطار السابق.
وتساوي الموضع الناتج 55.861.278 حق التصويت. لم تُبلَّغ عن أدوات مالية؛ تشير الإخطار إلى الإتمام في لندن في 23-أكتوبر-2025 وتذكر عدم وجود معلومات إضافية.
Genflow Biosciences (OTC:GENFF) 披露显示 Jonathan Mark Swann 将其持股增至 11.32% 的投票权，於 2025-10-23，高于先前通知中的 8.40%。
由此产生的位置等于 55,861,278 投票权。未报告金融工具；通知在 伦敦 的完成日期为 2025-10-23，并表示没有其他信息。
- Holding increased from 8.40% to 11.32% on 23-Oct-2025
- Resulting stake equals 55,861,278 voting rights
- Single holder now holds 11.32% of voting rights as of 23-Oct-2025
LONDON, UK / ACCESS Newswire / October 24, 2025 / TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00BP2C3V08 |
Issuer Name
GENFLOW BIOSCIENCES PLC |
UK or Non-UK Issuer
UK |
2. Reason for Notification
An acquisition or disposal of voting rights |
3. Details of person subject to the notification obligation
Name
Jonathan Mark Swann |
City of registered office (if applicable)
rickmansworth |
Country of registered office (if applicable)
United Kingdom |
4. Details of the shareholder
Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above
City of registered office (if applicable)
Country of registered office (if applicable)
5. Date on which the threshold was crossed or reached
23-Oct-2025 |
6. Date on which Issuer notified
23-Oct-2025 |
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8.A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer | |
Resulting situation on the date on which threshold was crossed or reached | 11.320000 | 0.000000 | 11.320000 | 55861278 |
Position of previous notification (if applicable) | 8.400000 | 0.000000 | 8.400000 | 36588550 |
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
Class/Type of shares ISIN code(if possible) | Number of direct voting rights (DTR5.1) | Number of indirect voting rights (DTR5.2.1) | % of direct voting rights (DTR5.1) | % of indirect voting rights (DTR5.2.1) |
GB00BP2C3V08 | 55861278 | 0 | 11.320000 | 0.000000 |
Sub Total 8.A | 55861278 | |||
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
Type of financial instrument | Expiration date | Exercise/conversion period | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights |
Sub Total 8.B1 | ||||
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
Type of financial instrument | Expiration date | Exercise/conversion period | Physical or cash settlement | Number of voting rights | % of voting rights |
Sub Total 8.B2 | |||||
9. Information in relation to the person subject to the notification obligation
1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. |
Ultimate controlling person | Name of controlled undertaking | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold |
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
NONE |
12. Date of Completion
23-Oct-2025 |
13. Place Of Completion
London |
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
Who increased their stake in Genflow Biosciences (GENFF) on 23-Oct-2025?
What voting rights does Jonathan Mark Swann hold in GENFF after the 23-Oct-2025 notification?
How much did the GENFF holding change from the prior notification?
Were any financial instruments reported in the GENFF 23-Oct-2025 disclosure?
When and where was the GENFF major-holdings notification completed?
